Practical Considerations for Biosimilars

Upon successful completion of this course, learners should be able to:
1. Discuss common barriers to biosimilar use
2. Develop strategies to improve patient access to care through the use of biosimilars
3. Review factors that impact the regulation of biosimilar use
4. Identify relevant state-based guidance for managing biosimilar switching and substituting
5. Recognize the unique properties of an insulin that make it difficult to replicate and manufacture.
6. Evaluate the use of interchangeable biosimilar insulin in a pharmacy practice setting.

Kelly Brunk, PharmD, BCOP
Clinical Oncology Pharmacist
The University of Kansas HealthSystems

John A. Galdo, PharmD, MBA, BCPS, BCGP (Jake)
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad, Inc

Dr. Brunk and Dr. Galdo have no relevant financial relationships with ineligible companies to disclose.

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable
Initial Release Date: October 1, 2022
Planned Expiration Date: October 1, 2025

Universal Activity Number (UAN): 0107-0000-22-369-H01-P

Application-based CPE Activity

CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at www.MyCPEMonitor.net.

¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.

Additional information

Duration	1h 0m
Topic Designator	Disease State/Drug Therapy
ACPE	Yes
ACPE Topic	01 Drug Therapy
Role	Pharmacist
Media-Type	Written
Release Date	10/1/22
CEUs	0.1
Rating	4
ACPE Number	0107-0000-22-369-H01-P